Windward Bio targets $1B valuation in Nasdaq IPO
What's the deal? Swiss drug developer Windward Bio Group AG is seeking a valuation of up to $1 billion in its US initial public offering. The Basel-based company plans to raise up to $185.3 million by selling roughly 10.3 million shares priced between $16 and $18. It will list on the Nasdaq under the ticker "WWB."
What's the endgame? Windward develops antibody medicines for serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis. Proceeds are aimed at advancing its respiratory-drug trials. Its lead asthma drug targets TSLP, the same mechanism as approved Tezspire, with Windward betting on less frequent dosing.
Who's backing it? Windward has raised $310 million in equity financing from Novo HoldingsDealroom has a profile for this one. Try Dealroom →, OrbiMed, Blue Owl, and RTW InvestmentsDealroom has a profile for this one. Try Dealroom →. French drugmaker Sanofi has agreed to buy $50 million of shares and pre-funded warrants in a concurrent private placement. Jefferies, TD Cowen, Piper Sandler, and UBS Investment BankDealroom has a profile for this one. Try Dealroom → are underwriting the offering.
Why now? Healthcare, seen as a defensive sector, has anchored this year's fall IPO window as choppy markets and rising borrowing costs weigh on other sectors. All seven US IPOs in October were in healthcare, raising $1.2 billion. Drug developer Rezera also launched its roadshow last week and is expected to go public in New York this week.
What could go wrong? October's first-day results varied, showing investor appetite is not a blanket endorsement. Windward's roughly $1 billion valuation rests substantially on upcoming trial evidence, with early asthma results expected in the first half of 2027.
The signal: A biotech-heavy but selective IPO market is rewarding companies with strong institutional backing, yet the ultimate test for Windward is clinical differentiation against an already-approved rival.
Read more: Reuters
Image credit: Generated with Gemini
